SG11201900910TA - RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION - Google Patents

RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Info

Publication number
SG11201900910TA
SG11201900910TA SG11201900910TA SG11201900910TA SG11201900910TA SG 11201900910T A SG11201900910T A SG 11201900910TA SG 11201900910T A SG11201900910T A SG 11201900910TA SG 11201900910T A SG11201900910T A SG 11201900910TA SG 11201900910T A SG11201900910T A SG 11201900910TA
Authority
SG
Singapore
Prior art keywords
madison
international
arrowhead
hepatitis
pharmaceuticals
Prior art date
Application number
SG11201900910TA
Inventor
Zhen Li
Rui Zhu
Christine I Wooddell
Bruce D Given
Tao Pei
David L Lewis
Lauren J Almeida
David B Rozema
Darren H Wakefield
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of SG11201900910TA publication Critical patent/SG11201900910TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIPO I PCT 011111010 n °nolo oio 11o1 IIII 11111°1111°111 (10) International Publication Number WO 2018/027106 A3 (51) International Patent Classification: C07H 21/02 (2006.01) A61K 48/00 (2006.01) (21) International Application Number: PCT/US2017/045446 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,754 04 August 2016 (04.08.2016) US 62/534,733 20 July 2017 (20.07.2017) US 62/540,639 03 August 2017 (03.08.2017) US (71) Applicant: ARROWHEAD PHARMACEUTICALS, INC. [US/US]; 225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 (US). (72) Inventors: LI, Zhen; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). ZHU, Rui; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madi- son, WI 53719 (US). WOODDELL, Christine I.; Arrow- head Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). GIVEN, Bruce D.; Arrowhead Pharma- ceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). PEI, Tao; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). LEWIS, David L.; 2930 Lakeland Avenue, Madison, WI 53704 (US). ALMEIDA, Lauren J.; 490 Togstad Glenn, Madison, WI 53711 (US). ROZEMA, David B.; 4361 Gils Way, Cross Plains, WI 53528 (US). WAKEFIELD, Darren H.; 5236 Stoneman Drive, Fitchburg, WI 53711 (US). (74) Agent: TEIGEN, Robert Michael; Arrowhead Pharma- ceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 15 March 2018 (15.03.2018) Cr) O 1-1 (54) Title: RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION \" (57) : Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents N to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV C infection.
SG11201900910TA 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION SG11201900910TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370754P 2016-08-04 2016-08-04
US201762534733P 2017-07-20 2017-07-20
US201762540639P 2017-08-03 2017-08-03
PCT/US2017/045446 WO2018027106A2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Publications (1)

Publication Number Publication Date
SG11201900910TA true SG11201900910TA (en) 2019-02-27

Family

ID=61073185

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913585SA SG10201913585SA (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
SG11201900910TA SG11201900910TA (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913585SA SG10201913585SA (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Country Status (22)

Country Link
US (5) US10780108B2 (en)
EP (2) EP4364808A2 (en)
JP (3) JP7237816B2 (en)
KR (4) KR102540359B1 (en)
CN (2) CN116514890A (en)
AU (2) AU2017306692B2 (en)
BR (1) BR112019002117A2 (en)
CA (2) CA3229270A1 (en)
CL (4) CL2019000278A1 (en)
CO (1) CO2019002017A2 (en)
CR (3) CR20220469A (en)
EC (1) ECSP19015395A (en)
IL (2) IL305507A (en)
JO (2) JOP20170161A1 (en)
MA (1) MA45863A (en)
MX (3) MX2019001493A (en)
PE (1) PE20190567A1 (en)
PH (1) PH12019500245A1 (en)
SG (2) SG10201913585SA (en)
TW (1) TW202334420A (en)
UY (1) UY37353A (en)
WO (1) WO2018027106A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430196A (en) 2011-06-30 2021-09-24 箭头药业股份有限公司 Compositions and methods for inhibiting gene expression of hepatitis b virus
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20170161A1 (en) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
KR102634762B1 (en) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 Alpha-v beta-6 integrin ligands and uses thereof
RS63836B1 (en) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Products and compositions
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
JP7353276B2 (en) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド How to treat hepatitis B infection
TN2020000059A1 (en) 2017-11-01 2022-01-06 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN110944675A (en) 2017-12-01 2020-03-31 苏州瑞博生物技术有限公司 Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
WO2019105414A1 (en) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2019105419A1 (en) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Nucleic acid, composition and conjugate containing same, preparation method, and use
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
MX2021001056A (en) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF.
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. Sirna conjugate, preparation method therefor and use thereof
HRP20231338T1 (en) * 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Combination hbv therapy
WO2020163747A1 (en) * 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MA55720A (en) * 2019-04-18 2022-02-23 Janssen Pharmaceuticals Inc MULTIPLE THERAPY FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
CN114340664A (en) * 2019-06-18 2022-04-12 爱尔兰詹森科学公司 Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi
CN110218728A (en) * 2019-06-28 2019-09-10 厦门甘宝利生物医药有限公司 A kind of noval chemical compound and its application
US20240033278A9 (en) * 2020-06-10 2024-02-01 Medshine Discovery Inc. Conjugate group and conjugate
JP2023531682A (en) * 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Compositions and methods for treatment of hepatitis D virus infection
KR20230066587A (en) 2020-09-11 2023-05-16 애로우헤드 파마슈티컬스 인코포레이티드 Lipid Conjugates for Delivery of Therapeutics
TW202227102A (en) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 Method of treating fatty liver disease
WO2022078479A1 (en) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN116916935A (en) * 2020-12-18 2023-10-20 奥利克斯医药有限公司 RNAi preparation for inhibiting hepatitis B virus expression and application thereof
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) * 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
CN117858949A (en) * 2021-05-28 2024-04-09 箭头药业股份有限公司 RNAi agents for inhibiting expression of mucin 5AC (MUC 5 AC), compositions thereof, and methods of use thereof
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2023246750A1 (en) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 Double-stranded ribonucleic acid for inhibiting hepatitis b virus
WO2024015796A1 (en) * 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DK0452457T3 (en) 1989-11-03 1998-03-02 Univ Vanderbilt Method for in vivo removal of functional foreign genes
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
ATE239484T1 (en) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc DERIVATIZED OLIGONUCLEOTIDES WITH IMPROVED ABSORPTION CAPACITY
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
NL9201440A (en) 1992-08-11 1994-03-01 Univ Leiden Triantennary cluster glycosides, their preparation and application.
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5856459A (en) 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
AU6430599A (en) 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
US5977341A (en) 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
DK1102785T3 (en) 1999-06-07 2013-05-13 Arrowhead Res Corp Compositions for drug delivery using pH-sensitive molecules
US7019113B2 (en) 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
CA2442092A1 (en) 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US9994853B2 (en) * 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1627061B1 (en) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6635428B2 (en) 2001-12-04 2003-10-21 Quest Diagnostics Investments Incorporated Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP2258847B2 (en) 2002-08-05 2020-07-01 Silence Therapeutics GmbH Futher novel forms of interfering RNA molecules
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
CN1257284C (en) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 Method of blocking expression of hepatitis B virus
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
WO2005021751A1 (en) 2003-09-01 2005-03-10 Patrick Arbuthnot A self-processing rna expression cassette
JP2007520461A (en) 2003-12-16 2007-07-26 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Methods and compounds for altering hepatitis virus load
WO2005065719A1 (en) 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2006017932A1 (en) 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CN101142316A (en) 2005-03-09 2008-03-12 牧岩生命工学研究所 Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
DK1866414T3 (en) 2005-03-31 2012-04-23 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
CN101426912A (en) 2005-08-17 2009-05-06 瑟纳治疗公司 Chemically modified short interfering nucleic acid molecules that mediate RNA interference
RU2418068C2 (en) 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Chemically modified short interfering nucleic acid molecules that mediate rna interference
CA2619876A1 (en) 2005-08-17 2007-02-22 Sirna Therapeutics, Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US20070197460A1 (en) 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
CN100447243C (en) 2005-11-15 2008-12-31 中国人民解放军第四军医大学 HBV specificity interference target point gene and its siRNA and application in anti HBV infecting thereof
CN101024088A (en) 2006-02-20 2007-08-29 桂林医学院 B-type hepatitis virus micro ribonucleic-acid interference moleculars and its designing method
WO2008119000A1 (en) 2007-03-27 2008-10-02 University Of Iowa Research Foundation Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
CN101755049B (en) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 Primary micro RNA expression cassette
KR20100069679A (en) 2007-09-17 2010-06-24 재단법인 목암생명공학연구소 Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
WO2009045457A2 (en) 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
CN101603042B (en) 2008-06-13 2013-05-01 厦门大学 RNA interference target for treating hepatitis B virus infection
CN101322847A (en) 2008-06-23 2008-12-17 淮安市第四人民医院 Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CA3151965A1 (en) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
JP2012525146A (en) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Overcharged protein for cell penetration
US9012225B2 (en) 2009-05-05 2015-04-21 Miragen Therapeutics Lipophilic polynucleotide conjugates
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
US9050375B2 (en) 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
MX2012009178A (en) 2010-02-24 2012-11-30 Arrowhead Res Corp Compositions for targeted delivery of sirna.
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
KR102072631B1 (en) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2616543A1 (en) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
CN101948834B (en) 2010-09-16 2012-07-04 山东大学 siRNA for treating HBV
PL3124610T3 (en) 2010-10-28 2019-09-30 Benitec Biopharma Limited Hbv treatment
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
BR122020024388B1 (en) 2010-12-29 2021-09-21 F. Hoffmann-La Roche Ag OLIGONUCLEOTIDE AND PHARMACEUTICAL COMPOSITION
RU2667524C2 (en) 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Modulation of hepatitis b virus (hbv) expression
EP2709989B8 (en) 2011-05-18 2018-04-18 Janssen Sciences Ireland UC Quinazoline derivatives for the treatment of viral infections and further diseases
CN113430196A (en) 2011-06-30 2021-09-24 箭头药业股份有限公司 Compositions and methods for inhibiting gene expression of hepatitis b virus
TWI623618B (en) 2011-07-12 2018-05-11 傳斯堅公司 Hbv polymerase mutants
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
KR20220045091A (en) 2011-11-18 2022-04-12 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
MX2014001965A (en) 2012-04-18 2014-03-31 Arrowhead Res Corp Poly(acrylate) polymers for in vivo nucleic acid delivery.
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
US9212363B2 (en) 2012-05-11 2015-12-15 City Of Hope RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
LT3401400T (en) 2012-05-25 2019-06-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN103333890B (en) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 RNA interference preparation used for treating viral hepatitis B
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
WO2015050871A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compounds to treat hepatitis b virus
EP4223315A3 (en) 2014-05-01 2023-08-23 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
CN104059916A (en) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 Sequence of hepatitis B virus (HBV) specific microRNA like siRNA (msiRNA) and application thereof
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
CN108136206B (en) 2015-07-17 2021-10-15 阿克丘勒斯治疗公司 Anti-hepatitis B virus composition and medicament and application thereof
CN108350455A (en) 2015-07-29 2018-07-31 阿布特斯生物制药公司 Composition for making hepatitis B virus silenced gene expression and method
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
CN113797348A (en) 2016-03-07 2021-12-17 箭头药业股份有限公司 Targeting ligands for therapeutic compounds
MA45478A (en) 2016-04-11 2019-02-20 Arbutus Biopharma Corp TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS
JOP20170161A1 (en) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
EP3506913A4 (en) 2016-09-02 2020-06-10 Arrowhead Pharmaceuticals, Inc. Targeting ligands
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
EA202091517A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
TW201945003A (en) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2020163747A1 (en) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MX2021013698A (en) 2019-05-13 2021-12-10 Vir Biotechnology Inc Compositions and methods for treating hepatitis b virus (hbv) infection.
CN114340664A (en) 2019-06-18 2022-04-12 爱尔兰詹森科学公司 Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi
KR20230050328A (en) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 RNA replicon vaccine against HBV
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection

Also Published As

Publication number Publication date
JP2019527694A (en) 2019-10-03
US10780108B2 (en) 2020-09-22
MX2020011805A (en) 2020-12-07
CA3032945A1 (en) 2018-02-08
AU2017306692A1 (en) 2019-02-21
KR102540359B1 (en) 2023-06-02
MA45863A (en) 2019-06-12
AU2022205929A1 (en) 2022-10-06
PH12019500245A1 (en) 2019-10-14
IL264575B2 (en) 2024-02-01
JP7237816B2 (en) 2023-03-13
NZ750390A (en) 2023-11-24
CR20190056A (en) 2019-05-20
US20220079973A1 (en) 2022-03-17
TW202018081A (en) 2020-05-16
WO2018027106A2 (en) 2018-02-08
ECSP19015395A (en) 2019-06-30
TW202334420A (en) 2023-09-01
KR102650107B1 (en) 2024-03-20
US20190255091A1 (en) 2019-08-22
SG10201913585SA (en) 2020-02-27
KR20190038606A (en) 2019-04-08
JOP20170161A1 (en) 2019-01-30
IL264575A (en) 2019-02-28
MX2019001493A (en) 2019-07-12
US11590156B2 (en) 2023-02-28
IL264575B1 (en) 2023-10-01
US11517584B2 (en) 2022-12-06
EP4364808A2 (en) 2024-05-08
CN109843902A (en) 2019-06-04
JP2023123469A (en) 2023-09-05
KR20240039232A (en) 2024-03-26
KR20230025949A (en) 2023-02-23
CL2021001195A1 (en) 2021-10-22
CL2022001478A1 (en) 2023-01-13
CL2019000278A1 (en) 2020-03-20
CN109843902B (en) 2023-05-30
US20230355651A1 (en) 2023-11-09
US20210100829A1 (en) 2021-04-08
CR20220468A (en) 2023-05-12
KR20230084607A (en) 2023-06-13
US20190292547A1 (en) 2019-09-26
CA3229270A1 (en) 2018-02-08
CR20220469A (en) 2022-10-26
MX2020011806A (en) 2020-12-07
EP3494123A2 (en) 2019-06-12
BR112019002117A2 (en) 2019-07-09
EP3494123A4 (en) 2020-07-22
JP2022068222A (en) 2022-05-09
PE20190567A1 (en) 2019-04-22
UY37353A (en) 2018-02-28
CN116514890A (en) 2023-08-01
JOP20190015A1 (en) 2019-02-04
WO2018027106A3 (en) 2018-03-15
AU2017306692B2 (en) 2022-08-04
KR102500675B1 (en) 2023-02-15
IL305507A (en) 2023-10-01
CL2020002156A1 (en) 2020-12-18
CO2019002017A2 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
SG11201900910TA (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
SG11201901841TA (en) Targeting ligands
SG11201908547VA (en) Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
SG11201806340YA (en) Zika virus vaccine
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201901364VA (en) Engineered target specific nucleases
SG11201810594RA (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
SG11201907846VA (en) Therapeutic rna
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201908569QA (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
SG11201909011PA (en) Niraparib compositions
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201808528VA (en) Modified wound dressings
SG11201808003RA (en) Bromodomain inhibitors
SG11201900464TA (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine